These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 29927585)

  • 41. A Bioorthogonal Near-Infrared Fluorogenic Probe for mRNA Detection.
    Wu H; Alexander SC; Jin S; Devaraj NK
    J Am Chem Soc; 2016 Sep; 138(36):11429-32. PubMed ID: 27510580
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Mexitil, a new anti-arrhythmia agent].
    Heinrich K
    Med Klin; 1980 Mar; 75(6):235-7. PubMed ID: 7393119
    [No Abstract]   [Full Text] [Related]  

  • 43. [Use of an anti-arrhythmia drug mexicord in the treatment of ventricular extrasystole].
    Urumbaev RK; Suprunova IP; Imanakunova DSh; Rakhimova GR
    Kardiologiia; 1992 Mar; 32(3):48-50. PubMed ID: 1383590
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combination therapy with mexiletine and sotalol suppresses inherited ventricular arrhythmias in German shepherd dogs better than mexiletine or sotalol monotherapy: a randomized cross-over study.
    Gelzer AR; Kraus MS; Rishniw M; Hemsley SA; Moïse NS
    J Vet Cardiol; 2010 Aug; 12(2):93-106. PubMed ID: 20663731
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Site-Specific In Vivo Bioorthogonal Ligation via Chemical Modulation.
    Koo H; Lee JH; Bao K; Wu Y; El Fakhri G; Henary M; Yun SH; Choi HS
    Adv Healthc Mater; 2016 Oct; 5(19):2510-2516. PubMed ID: 27568818
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical pharmacokinetics of mexiletine.
    Labbé L; Turgeon J
    Clin Pharmacokinet; 1999 Nov; 37(5):361-84. PubMed ID: 10589372
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Switchable Lipids: Conformational Change for Fast pH-Triggered Cytoplasmic Delivery.
    Viricel W; Mbarek A; Leblond J
    Angew Chem Int Ed Engl; 2015 Oct; 54(43):12743-7. PubMed ID: 26189870
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Experience with the combined use of 1st- and 2d-group anti-arrhythmic preparations in patients with refractory arrhythmia].
    Abdalla A; Mazur NA
    Klin Med (Mosk); 1988 Jun; 66(6):40-3. PubMed ID: 2460667
    [No Abstract]   [Full Text] [Related]  

  • 49. A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. AIDS Clinical Trial Group 242 Protocol Team.
    Kieburtz K; Simpson D; Yiannoutsos C; Max MB; Hall CD; Ellis RJ; Marra CM; McKendall R; Singer E; Dal Pan GJ; Clifford DB; Tucker T; Cohen B
    Neurology; 1998 Dec; 51(6):1682-8. PubMed ID: 9855523
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Possible mechanism for pharmacokinetic interaction between lidocaine and mexiletine.
    Maeda Y; Funakoshi S; Nakamura M; Fukuzawa M; Kugaya Y; Yamasaki M; Tsukiai S; Murakami T; Takano M
    Clin Pharmacol Ther; 2002 May; 71(5):389-97. PubMed ID: 12011825
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bioorthogonal Decaging Reactions for Targeted Drug Activation.
    Davies S; Stenton BJ; Bernardes GJL
    Chimia (Aarau); 2018 Nov; 72(11):771-776. PubMed ID: 30514419
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mexiletine and tocainide: a profile of two lidocaine analogs.
    Woosley RL
    Ration Drug Ther; 1987 Mar; 21(3):1-7. PubMed ID: 3116601
    [No Abstract]   [Full Text] [Related]  

  • 53. Simultaneous drug release at different rates from biodegradable polyurethane foams.
    Sivak WN; Zhang J; Petoud S; Beckman EJ
    Acta Biomater; 2009 Sep; 5(7):2398-408. PubMed ID: 19398389
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Pharmacokinetics and biological availability of drug forms of mexiletine in dogs].
    Mahrla Z; Augustiniová B; Sidlíková I; Lupták D; Ostrovská V; Kovácová D; Svobodová X; Baricic P; Durisová M
    Bratisl Lek Listy; 1986 Feb; 85(2):160-70. PubMed ID: 3955402
    [No Abstract]   [Full Text] [Related]  

  • 55. In vivo and in vitro taste masking of ofloxacin and sustained release by forming interpenetrating polymer network beads.
    Rajesh AM; Popat KM
    Pharm Dev Technol; 2017 Feb; 22(1):26-34. PubMed ID: 26758556
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibitory effects of antiarrhythmic drugs on phenacetin O-deethylation catalysed by human CYP1A2.
    Kobayashi K; Nakajima M; Chiba K; Yamamoto T; Tani M; Ishizaki T; Kuroiwa Y
    Br J Clin Pharmacol; 1998 Apr; 45(4):361-8. PubMed ID: 9578183
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synthesis and characterization of new derivatives of alginic acid and evaluation of their iron(III)-crosslinked beads as potential controlled release matrices.
    Abulateefeh SR; Khanfar MA; Al Bakain RZ; Taha MO
    Pharm Dev Technol; 2014 Nov; 19(7):856-67. PubMed ID: 24032476
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Introducing bioorthogonal functionalities into proteins in living cells.
    Hao Z; Hong S; Chen X; Chen PR
    Acc Chem Res; 2011 Sep; 44(9):742-51. PubMed ID: 21634380
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mexiletine: pharmacology and therapeutic use.
    Manolis AS; Deering TF; Cameron J; Estes NA
    Clin Cardiol; 1990 May; 13(5):349-59. PubMed ID: 2189614
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Click and release: bioorthogonal approaches to "on-demand" activation of prodrugs.
    Ji X; Pan Z; Yu B; De La Cruz LK; Zheng Y; Ke B; Wang B
    Chem Soc Rev; 2019 Feb; 48(4):1077-1094. PubMed ID: 30724944
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.